TABLE 2.
Antimicrobial susceptibility of Salmonella isolate CFSA231 and CFSA629 to a further panel of antimicrobial agents and acquired antimicrobial resistance-encoding genes identified in the bacterial genome with online retrieval in Resfinder database.
| CFSA231 | CFSA629 | CFSA231 | CFSA629 | |||||||
| Antimicrobial class | Antimicrobial agent (abbreviation) | MIC (mg/L) | R/I/Sa | MIC (mg/L) | R/I/Sa | Resistance genes | Resistance genes | |||
|
or point mutation |
or point mutation |
|||||||||
| Chromosome | Plasmid | Chromosome | Plasmid | |||||||
| β-lactam combination agents | Ampicillin/sulbactam (SAM) | ≥32/16 | R | ≥32/16 | R | blaOXA–1 | blaTEM–1B | blaCTX–M–14 | ||
| Penicillins | Ampicillin (AMP) | ≥32 | R | ≥32 | R | |||||
| Cephalosporins | Cefotaxime (CTX) | 0.12 | S | 64 | R | |||||
| Cefotaxime + clavulanate (CTX + CLA) | 0.06/4 | – | 0.12/4 | – | ||||||
| Ceftazidime (CAZ) | 0.5 | S | 2 | S | ||||||
| Ceftazidime + clavulanate (CAZ + CLA) | 0.25/4 | – | 0.25/4 | – | ||||||
| Cephalothin (KF) | 2 | S | ≥32 | R | ||||||
| Cefoxitin (FOX) | 2 | S | 8 | S | ||||||
| Ceftriaxone (CRO) | 0.12 | S | ≥4 | R | ||||||
| Cefepime (FEP) | 2 | S | ≥16 | R | ||||||
| Carbapenems | Imipenem (IMP) | 0.25 | S | 0.25 | S | |||||
| Meropenem (MEM) | 0.03 | S | 0.03 | S | ||||||
| Ertapenem (ETP) | 0.015 | S | 0.5 | S | ||||||
| Monobactams | Aztreonam (ATM) | 0.06 | S | 4 | S | |||||
| Aminoglycosides | Gentamicin (GEN) | ≥16 | R | 8 | I | aac(3)-IV, aac(6′)-Iaa, aac(6′)-Ib-cr, aadA1, aadA2,aaaA2b, aadA8b, aph(3′)-Ia, aph(4)-Ia | aac(6′)-Iaa, aph(3′′)-Ib, aph(6)-Id | aac(3)-IV, aph(4)-Ia | ||
| Amikacin(AK) | 8 | S | 1 | S | ||||||
| Tetracyclines | Tetracycline (TET) | ≥16 | R | ≥16 | R | tetA | tetB | |||
| Tigecycline (TGC) | 0.12 | S | 0.25 | S | ||||||
| (Fluoro)Quinolones | Nalidixic acid (NAL) | ≥32 | R | ≥32 | R | ParC T57S; aac(6′)-Ib-cr, oqxA, oqxB, qnrS2 | GyrA D87Y | |||
| Ciprofloxacin (CIP) | 4 | R | 0.5 | I | ||||||
| Folate pathway inhibitors | Trimethoprim/sulfamethoxazole (SXT) | ≥8/152 | R | 0.25/4.75 | S | sul1, sul2, sul3, dfrA12 | sul2 | |||
| Trimethoprim(TMP) | ≥16 | R | 0.25 | S | ||||||
| Phenicols | Chloramphenicol (CHL) | ≥32 | R | 8 | S | catB3, cmlA1, floR | ||||
| Florfenicol (FFC)b,c | ≥16 | R | 8 | I | ||||||
| Nitrofurans | Nitrofurantoin (NIT) | 32 | S | 16 | S | |||||
| Polymyxins | Polymyxin E (Colistin, CT)c,d | 2 | S | 4 | R | mcr-1.1 | mcr-1.19 | |||
| Polymyxin B (PB)d | 4 | I | 4 | I | ||||||
| Fosfomycins | Fosfomycin (FOS) | –e | –e | –e | –e | fosA7 | fosA3 | |||
R, resistant; I, intermediate; S, susceptible; aR/I/S according to the CLSI guidelines M100-S28, 2018; bR/I/S according to the CLSI guidelines M31-A3, 2008; cused as a feed additive in animal production; dR/I/S according to EUCAST clinical breakpoints, 2018; eno data.